Numerous studies have linked controlled psychedelics to improvements in mental health conditions such as depression and PTSD. In March, the FDA approved Esketamine as a treatment for depression. However, with much stigma surrounding psychedelics, researchers question how many patients would take psychedelic medications if prescribed to them. According to a new study, 40% of people with no experience of psychedelics would be unlikely to take the prescription due to fears of 'brain damage' or a 'bad trip'.
